PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease

Bekker P., Keshav S., Johnson D., Schall T.

DOI

10.1097/00054725-200912002-00030

Type

Conference paper

Publication Date

12/2009

Volume

15

Pages

S11 - S11

Permalink Original publication